Does ppi therapy predispose to Clostridium difficile infection?

Nature Reviews Gastroenterology and Hepatology

Volumn 6, Issue 9, 2009, Pages 555-557

  Pant, Chaitanya ^a   Madonia, Phillip ^a   Minocha, Anil ^a  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; HISTAMINE H2 RECEPTOR ANTAGONIST; PROTON PUMP INHIBITOR;

ABDOMINAL PAIN; AGE; ALBUMIN BLOOD LEVEL; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL GROWTH; CLOSTRIDIUM DIFFICILE INFECTION; COMORBIDITY; CONSTIPATION; DIARRHEA; DRUG INDUCED HEADACHE; HUMAN; INFECTION RISK; INTESTINE FLORA; LENGTH OF STAY; NAUSEA; PRIORITY JOURNAL; RASH; SEX DIFFERENCE; STOMACH PH; XEROSTOMIA;

ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; ENTEROCOLITIS, PSEUDOMEMBRANOUS; ESOPHAGITIS; GASTRIC ACID; HUMANS; PEPTIC ULCER; PROTON PUMP INHIBITORS; RISK FACTORS;

EID: 69949085909     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2009.128     Document Type: Article

References (29)

1. Archibald, L. K., Baurjee, S. H. & Jarvis, W. R. secular trends in hospital acquired C. diff disease in the Us from 1987-2001. J. Infect. Dis. 189, 1585-1589 (2004).
2. Fekety, R. & Shah, A. B. Diagnosis and treatment of Clostridium difficile colitis. JAMA 269, 71-75 (1993).
3. Miller, M. A. et al. Morbidity, mortality, and healthcare burden of nosocomial Clostridium difficile-associated diarrhea in canadian hospitals. Infect. Control Hosp. Epidemiol. 23, 137-140 (2002).
4. Kyne, L., Hamel, M. B., polavaram, R. & Kelly, C. P. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin. Infect. Dis. 34, 346-353 (2002).
5. Deshpande, A., Pant, C., Jain, A., Fraser, T. G. & Rolston, D. D. Do fluoroquinolones predispose patients to Clostridium difficile associated disease? A review of the evidence. Curr. Med. Res. Opin. 24, 329-333 (2008).
6. O'connor, J., Johnson, S. & Gerding, D. C. diff infection caused by the epidemic B1/NAp1/O27 strain. Gastroenterology 136, 1913-1924 (2009).
7. Bartlett, J. & Perl, T. the new Clostridium difficile - what does it mean? N. Engl. J. Med. 353, 2503-2505 (2005).
8. Cunningham, R. & Dial, S. is overuse of proton pump inhibitors fueling the current epidemic of Clostridium difficile associated diarrhea? J. Hosp. Infect. 70, 1-6 (2008).
9. Williams, C. & Mccoll, K. E. review article: Proton pump inhibitors and bacterial overgrowth. Aliment. Pharmacol. Ther. 23, 3-10 (2006).
10. Jump, R. L., pultz, M. J. & Donskey, C. J. vegetative Clostridium difficile survives in room air on moist surfaces and in gastric contents with reduced acidity: A potential mechanism to explain the association between proton pump inhibitors and C. difficile-associated diarrhea? Antimicrob. Agents Chemother. 51, 2883-2887 (2007).
11. Dial, S., Delaney, J. A., Barkun, A. N. & Suissa, S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 294, 2989-2995 (2005).
12. Louie, T. J. & Meddings, J. Clostridium difficile infection in hospitals: Risk factors and responses. CMAJ 171, 45-46 (2004).
13. Walker, K. J. et al. Clostridium difficile colonization in residents of long-term care facilities: Prevalence and risk factors. J. Am. Geriatr. Soc. 41, 940-946 (1993).
14. Shah, S., Lewis, A., Leopold, D., Dunstan, F. & Woodhouse, K. Gastric acid suppression does not promote clostridial diarrhoea in the elderly. QJM 93, 175-181 (2000).
15. Lowe, D. O., Mamdani, M. M., Kopp, A., Low, D. E. & Juurlink, D. N. proton pump inhibitors and hospitalization for Clostridium difficile associated disease: A populationbased study. Clin. Infect. Dis. 43, 1272-1276 (2006).
16. Pepin, J. et al. emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: A cohort study during an epidemic in Quebec. Clin. Infect. Dis. 41, 1254-1260 (2005).
17. Muto, C. A. et al. A large outbreak of Clostridium difficile associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect. Control Hosp. Epidemiol. 26, 273-280 (2005).
18. Al-tureihi, F. I., Hassoun, A., Wolf-Klein, G. & isenberg, H. Albumin, length of stay, and proton pump inhibitors: Key factors in Clostridium difficile-associated disease in nursing home patients. J. Am. Med. Dir. Assoc. 6, 105-108 (2005).
19. Cunningham, R., Dale, B., Undy, B. & Gaunt, N. proton pump inhibitors as a risk factor for Clostridium difficile diarrhoea. J. Hosp. Infect. 54, 243-245 (2003).
20. Dial, S., Alrasadi, K., Manoukian, C., Huang, A. & Menzies, D. risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: Cohort and case-control studies. CMAJ 171, 33-38 (2004).
21. Dial, S., Delaney, J. A., Schneider, V. & Suissa, S. proton pump inhibitor use and risk of community-acquired Clostridium difficile associated disease defined by prescription for oral vancomycin therapy. CMAJ 175, 745-748 (2006).
22. Yearsley, K. A. et al. proton pump inhibitor therapy is a risk factor for Clostridium difficile-associated diarrhea. Aliment. Pharmacol. Ther. 24, 613-619 (2006).
23. Leonard, J., Marshall, J. K. & Moayyedi, P. systematic review of the risk of enteric infection in patients taking acid suppression. Am. J. Gastroenterol. 102, 2047-2056 (2007).
24. Weiss, K. poor infection control, not fluoroquinolones, likely to be primary cause of Clostridium difficile associated diarrhea outbreaks in Quebec. Clin. Infect. Dis. 42, 725-727 (2006).
25. Cadle, R. M., Mansouri, M. D., Logan, N., Kudva, D. R. & Musher, D. M. Association of proton-pump inhibitors with outcomes in Clostridium difficile colitis. Am. J. Health Syst. Pharm. 64, 2359-2363 (2007).
26. Nardino, R. J., Vender, R. J. & Herbert, P. N. Overuse of acid-suppressive therapy in hospitalized patients. Am. J. Gastroenterol. 95, 3118-3122 (2000).
27. NHs National institute of Health and clinical excellence. Dyspepsia: managing dyspepsia in adults in primary care [online], http://guidance.nice.org.uk/cG17.
28. Sandvik, A. K., Brenna, e. & Waldum, H. L. review article: The pharmacological inhibition of gastric acid secretion - tolerance and rebound. Aliment. Pharmacol. Ther. 11, 1013-1018 (1997).
29. Dalton, B. R., Lye-Maccannell, T., Henderson, E. A., Maccannel, D. R. & Louie, T. J. proton pump inhibitors (PPI) significantly increase the risk of Clostridium difficile infection in a low endemicity, nonoutbreak hospital setting: Optimizing risk and benefit of ppi therapy. Aliment Pharmacol. Ther. 29, 626-634 (2008).